http://news.independent.co.uk/business/news/article2675849.ece
The five new oncology products set for launch by 2010 are the cervical
cancer vaccine Cervarix; the renal cancer drug Pazopanib; Promacta, an
oral compound to help cancer patients build up their platelet count and
reduce bleeding; Rezonic, which helps to control symptoms associated with
chemotherapy such as nausea; and Ofatumumab, an antibody to treat
leukaemia which has blockbuster potential.

Glaxo's head of research and development, Moncef Slaoui, called the target
"an unprecedented objective for a pharmaceutical company". He said Glaxo
was developing late-stage medicines in more than 12 types of cancer and
had a significant number of compounds in early-stage discovery.

For Glaxo's lung cancer trial, 2,200 patients diagnosed with non-small
cell lung cancer, the most common form of the disease, will be treated
with the vaccine. It is hoped the vaccine may prevent the cancer from
returning following surgery and will enable patients to live longer by
helping their immune systems to recognise and destroy cancer cells. Lung
cancer has one of the lowest survival rates, with 85 per cent of patients
dying within five years.